Oncology Peer Review On-The-Go: ScaleReady’s Work to Make Cell and Gene Therapy Practical and Viable

Podcast

CancerNetwork speaks with Josh Ludwig on its latest podcast to discuss ScaleReady’s plans to make cell and gene therapy more practical and viable moving forward.

This week, CancerNetwork spoke with Josh Ludwig, global director of commercial operations at ScaleReady, about how this joint venture between Bio-Techne, Fresenius Kabi, and Wilson Wolf, launched in January 2021, is uniquely positioned to make cell and gene therapy practical and viable for patients with cancer.

Ludwig elaborated on how ScaleReady can support the entire industry, now and into the future, with a manufacturing platform that delivers a high throughput and efficient use of space. He also discussed G-Rex closed-system bioreactors, important processes for successful commercialization of cell and gene therapy, and future efforts utilizing ScaleReady.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

Recent Videos
Standardizing surgical outcomes and better training oncologic surgeons may be accomplished through the use of AI.
The poly-ICLC trial seeks to develop a delivery mechanism to prostate cancer through different biomarkers.
Sympathomimetic effects related to psilocybin may preclude use among patients with coronary artery disease or those with a high risk of stroke.
Psilocybin-assisted psychotherapy may be integrated into pre-existing behavioral health aspects of comprehensive cancer treatment.
Psilocybin may help address a need for effective medication to aid those who have psychological challenges related to a serious cancer diagnosis.
Optimal cancer survivorship care may entail collaboration between a treating oncologist and a cancer survivorship expert.
Survivors of cancer may experience an increased risk of having organ, cardiac, or lung disease following prior anti-cancer therapy.
Performing ablation and injecting tumor sites with immunotherapy may be “synergistic”, according to Jason R. Williams, MD, DABR.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Related Content
Micheal P. Bogenschutz, MD, discussed addressing unmet needs, implementation, and adverse effects related to psilocybin-assisted psychotherapy in cancer.

Integrating Psilocybin-Assisted Psychotherapy in Comprehensive Cancer Care

Michael P. Bogenschutz, MD
January 20th 2025
Article

Micheal P. Bogenschutz, MD, discussed addressing unmet needs, implementation, and adverse effects related to psilocybin-assisted psychotherapy in cancer.

Michael P. Bogenschutz, MD, discusses the efficacy, safety, implementation, and future research of psilocybin for cancer-related psychological events.

Psilocybin May Help Address Cancer-Related Psychological Concerns

Michael P. Bogenschutz, MD
January 20th 2025
Podcast

Michael P. Bogenschutz, MD, discusses the efficacy, safety, implementation, and future research of psilocybin for cancer-related psychological events.

FDA Clears Investigational New Drug Application for R-5780 in Solid Tumors

FDA Clears Investigational New Drug Application for R-5780 in Solid Tumors

Tim Cortese
January 15th 2025
Article

The RISE R-5780-01 trial will evaluate the safety and tolerability of R-5780 in patients with melanoma, basal cell carcinoma, or squamous cell carcinoma.

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

Improving Quality of Life in Cancer With Physical Medicine & Rehabilitation

Jessica Cheng, MD
September 9th 2024
Podcast

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

Nearly half of patients with an ICD had a device programming encounter near the end of life, which could present an opportunity to discuss goals of care.

Aggressive End-of-Life Care More Likely in ICD Users with Advanced Cancers

Roman Fabbricatore
January 14th 2025
Article

Nearly half of patients with an ICD had a device programming encounter near the end of life, which could present an opportunity to discuss goals of care.

All patients who received HT-001 in the phase 2a CLEER-001 trial showed significant skin toxicity improvements by 6 weeks.

Topical Gel Significantly Improves EGFR Inhibitor-Related Skin Toxicity

Russ Conroy
January 11th 2025
Article

All patients who received HT-001 in the phase 2a CLEER-001 trial showed significant skin toxicity improvements by 6 weeks.